Also, immuno-oncology may be a promising approach for the treatment due to a correlation of PD-L1 expression in various sarcomas and poor overall survival [360] and monoclonal antibodies targeting PD-L1 (nivolumab) have already been used in clinical trials to treat pediatric sarcoma patients [361]. The gene discussed is CD274; the disease is sarcoma.